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Phenylketonuria (PKU) andCystic Fibrosis (CF)
have an incidence in Northern Ireland of 1 : 4000
and 1: 2000respectively (1994figures). Manage-
ment problems are dietary, disease-related and
psychological. Search of the literature has
revealed no previous report of a child with both
conditions.
We present the case of a child in whom both CF
and PKU were identified on routine neonatal
screening. The case highlights the value of this
procedure.
Case Report A female infant weighing 3370 g
wasbornbynormaldeliveryat39weeksgestation
to parents who believed that they were distantly
related. They had one other child, a female, aged
five years who was alive and well. There were no
perinatalproblemsbutanabnormalphenylalanine
result from routine neonatal Guthrie card
screening was confirmed by a plasma
phenylalanine concentration of 934 mcmol/l on
the fourteenth day (normal range 64-92 mcmol/l).
Urinary phenylalanine was elevated at45 mcmol/l
(normal range 4-17 mcmol/l) and urinary
phenylalanine excretion was 163 mcmol/mmol
creatinine. Protein, ketoacids and phenylketones
were absent from the urine. PKU was diagnosed
andshewascommencedonXPAnalog(Scientific
Hospital Supplies) together with 60 ml SMA
GoldCap(Wyeth) for3 days increasingto210ml
SMA Gold Cap to provide a small but essential
amount ofphenylalanine.
By 5 weeks of age concern was expressed about
a poor weight gain of 90 g from birth. Neonatal
screening had confirmed high immunoreactive
trypsinandsubsequent sweattestsrevealedraised
sodium concentration of 104 mmol/l. At 7 weeks
she was admitted to hospital for assessment and
management of CF. There were no respiratory
symptomsbutstoolswerelooseandfoul-smelling.
SerumvitaminAwaslowat0.61 mcmol/l(normal
range 1.1-3.5 mcmol/l), and serum vitamin E at
5.23 mcmol/l (normal range 16-35 mcmol/l).
Nutrizym GR(3) (Merck), flucloxacillin, and
vitamin supplements including vitamin E were
prescribed and physiotherapy commenced three
times daily. There was an increase in height and
weight velocity (Figure 1) and phenylalanine
tolerancefell(Figure2)followingthecommence-
ment ofpancreatic enzyme replacement therapy.
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Fig 1. Figure 1 shows height, weight and head
circumference data. Enzyme treatment
commenced at 7 weeks.
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Fig 2. Figure 2 shows the variation in phenylalanine intake (mg/kg/day) with chronogical age. Age of commencing
enzyme treatment is indicated by the perpendicular dotted line.
Atthe age ofeightmonths she was admitted with
a lower respiratory tract infection for intensive
physiotherapy. Prophylaxis with Augmentin
suspension, an aspartame-containing antibiotic
(7.015 mgphenylalanine/5 ml),wasinadvertently
prescribedforsix weeks althoughthedosage was
low (7.5 ml daily) and unlikely to have affected
phenylalanine control significantly.
Genotype analysis has shown that she is
homozygous for delta F 508, and also shows the
PKU mutations R408W, Y414C. At the age of
twenty-eightmonthssheismakinggoodprogress
withnormal development. Heightand weightare
bothjust above the fiftieth centile.
DISCUSSION
The case highlights the value of neonatal
screening. The chance of an individual having
both CFandPKU in ourpopulation is very low at
approximately 1:8,000,000 and we have been
unable to find any previous report of their
coexistence. It is possible that CF-related
malabsorptionmayhaveledtoalowerdiagnostic
plasma phenylalanine concentration than would
have otherwise occurred. Most patients with the
common CF genetic defect, the delta F508
mutation, have steatorrhoeal and there is also
known to be aspecific defect inthe absorption of
neutral amino acids in CF2. In our experience,
however, two other PKU patients with the PKU
mutations R408W, Y414C have had similar
plasmaphenylalanineconcentrations atdiagnosis
suggesting that malabsorption did not affect the
result.
Both conditions require skilled nutritional
intervention and monitoring by a dietitian. Their
coexistence requires a revision of all advice as
given for each occurring separately. The
management of PKU necessitates a diet with
smallcontrolled amounts ofnaturalprotein and a
daily intake of a protein substitute mixture to
meet requirements for normal growth and
development. Recommendations suggest a total
amino acid intake of3g/kg/day in children under
2 years of age and 2g/kg/day in children over 2
years.3Thistranslates as 3-4gprotein/kg/day and
2-3g protein/kg/day for under 2 years and over 2
years respectively. Energy requirements for
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individuals with PKU are comparable to those of
the general population. Patients who are
homozygous for the CF mutation delta F 508
have a significantly higherresting metabolic rate
( 21% predicted) than those ofothergenotypes.2
Theestimationofenergyandproteinrequirements
used at our centre are 120-150% ofrequirements
forageandaminimumof2g/kg/dayrespectively.4
In practical terms the two diets are compatible.
Fromdiagnosisourpatientwastreateddietetically
asaPKUpatient. Atpresentsheisreceiving most
of her protein requirements from a protein
substitute mixture. Low protein products
combined with energy supplements play an
important role in maintaining her energy intake
for appropriate growth and weight gain. Dietary
problems can be foreseen. Monotony and taste
fatigue are likely to occur because the PKU diet
islifelongandthereisalimitednumberofproducts
available. CF-related chronic respiratory
infections will cause an increase in metabolic
rate and in energy requirements.'
The psychological effects must be recognised.
Olsen5 has described the guilt, marital stress and
grief of parents on hearing the diagnosis of CF.
The parents of our patient are in the unique
position that their child has not one but two
chronic inherited diseases both diagnosed on
routine neonatal screening. The combinedrisk of
a further child with one or other condition is 1:2.
The child herself may suffer from lack of
understanding by teachers and peers.' Denial of
the severity of the illness may lead to non-
compliance.6
The prognosis of both conditions may be
influenced by the coexistence of the other. Poor
control of PKU with subsequent intellectual
deterioration may lead to non-compliance. Poor
control of CF with reduced growth velocity and
frequentinfectionswillleadtopoorphenylalanine
control andits consequences. Thefrequentuseof
antibiotics may lead to the child being
inadvertently given the aspartame-containing
antibiotic, Augmentin, in higher dosage than
occurred in our patient. Psychosocial problems
associated with CF are likely tobe aggravatedby
those of PKU.
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